ABVC BioPharma, Inc. (ABVC) vs Aligos Therapeutics, Inc. (ALGS)

ABVC BioPharma, Inc. and Aligos Therapeutics, Inc. are both Biotechnology companies. ABVC BioPharma, Inc. and Aligos Therapeutics, Inc. are of similar size ($34.0M and $32.6M). ABVC BioPharma, Inc. grew revenue faster over the last twelve months: 5,035.4% against 893.0%. ABVC BioPharma, Inc. has the higher net margin (0.00% vs −241.0%) and the higher return on invested capital (−33.5% vs −3,379.3%). Across the 16 metrics below, ABVC BioPharma, Inc. leads on 10 and Aligos Therapeutics, Inc. on 6.

Valuation

Metric ABVC ALGS Biotechnology median
P/E n/m n/m 7.88
P/S 22.77 1.82 11.47
P/B 2.42 1.80 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 24.03 0.86 10.73
Earnings yield (29.79%) (132.49%) (28.84%)
Free cash flow yield (9.14%) (164.46%) (23.03%)

Profitability

Metric ABVC ALGS Biotechnology median
Gross margin 99.97% 100.00% 65.16%
Operating margin 0.00% (250.63%) 0.00%
Net margin 0.00% (241.01%) 0.00%
Free cash flow margin 0.00% (299.90%) 0.00%
Return on equity (65.32%) (113.59%) (57.72%)
Return on assets (39.88%) (75.57%) (49.22%)
Return on invested capital (33.45%) (3,379.28%) 0.00%

Growth

Metric ABVC ALGS Biotechnology median
Revenue growth (TTM) 5,035.43% 893.01% 5.64%
EPS growth (last fiscal year) 7.14% 88.30% —
Revenue growth, 5-year CAGR (6.20%) — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ABVC ALGS Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 0.07 2.19 4.73
Net debt to EBITDA 0.21 0.87 0.96

Dividend

Metric ABVC ALGS Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ABVC ALGS Biotechnology median
Market cap 33.96m 32.60m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack